KR20210080388A - 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물 - Google Patents

안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물 Download PDF

Info

Publication number
KR20210080388A
KR20210080388A KR1020217011860A KR20217011860A KR20210080388A KR 20210080388 A KR20210080388 A KR 20210080388A KR 1020217011860 A KR1020217011860 A KR 1020217011860A KR 20217011860 A KR20217011860 A KR 20217011860A KR 20210080388 A KR20210080388 A KR 20210080388A
Authority
KR
South Korea
Prior art keywords
composition
patient
treatment
ocular surface
dryness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217011860A
Other languages
English (en)
Korean (ko)
Inventor
마르쿠스 바이어
다니엘라 빌렌
조냐 크뢰써
토마스 슐뤼터
Original Assignee
노바리크 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노바리크 게엠베하 filed Critical 노바리크 게엠베하
Publication of KR20210080388A publication Critical patent/KR20210080388A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020217011860A 2018-09-22 2019-09-20 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물 Pending KR20210080388A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP18196126 2018-09-22
EP18196126.9 2018-09-22
EP18198440 2018-10-03
EP18198440.2 2018-10-03
EP18202041.2 2018-10-23
EP18202041 2018-10-23
PCT/EP2019/075406 WO2020058504A1 (en) 2018-09-22 2019-09-20 Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness

Publications (1)

Publication Number Publication Date
KR20210080388A true KR20210080388A (ko) 2021-06-30

Family

ID=68240699

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217011860A Pending KR20210080388A (ko) 2018-09-22 2019-09-20 안구 표면 손상 및 건조 증상 치료를 위한 안약 조성물

Country Status (11)

Country Link
US (2) US20210346313A1 (https=)
EP (1) EP3852734A1 (https=)
JP (1) JP2022500461A (https=)
KR (1) KR20210080388A (https=)
CN (1) CN112739335A (https=)
AU (2) AU2019342426A1 (https=)
CA (1) CA3111873A1 (https=)
IL (1) IL281516A (https=)
PH (1) PH12021550621A1 (https=)
SG (1) SG11202102818YA (https=)
WO (1) WO2020058504A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108348777B (zh) 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
USRE50060E1 (en) 2016-06-23 2024-07-30 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
US10813976B2 (en) 2016-09-23 2020-10-27 Novaliq Gmbh Ophthalmic compositions comprising ciclosporin
PT3399962T (pt) 2016-12-23 2020-09-03 Novaliq Gmbh Composição oftálmica para o tratamento da doença do olho seco
CA3058097C (en) 2017-04-21 2024-01-02 Novaliq Gmbh Iodine compositions
KR20200059272A (ko) 2017-09-27 2020-05-28 노바리크 게엠베하 안구 질환의 치료에서의 사용을 위한 라타노프로스트를 포함하는 안과적 조성물
CN111182893A (zh) 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物
EP3758676A1 (en) 2018-03-02 2021-01-06 Novaliq GmbH Pharmaceutical compositions comprising nebivolol
KR102882058B1 (ko) 2018-03-28 2025-11-07 노바리크 게엠베하 티몰롤을 포함하는 약제학적 조성물
JP2021522219A (ja) 2018-04-27 2021-08-30 ノバリック ゲーエムベーハー 緑内障の治療のためのタフルプロストを含む眼科用組成物
CN113710228A (zh) 2019-02-13 2021-11-26 诺瓦利克有限责任公司 用于治疗眼部新生血管形成的组合物和方法
US12419933B2 (en) 2019-09-06 2025-09-23 Novaliq Gmbh Ophthalmic composition for the treatment of uveitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19938668B4 (de) 1999-08-14 2006-01-26 Bausch & Lomb Inc. Tränenersatzmittel
EP1494681A4 (en) * 2002-04-16 2008-08-06 Collagenex Pharm Inc PROCESS FOR THE SIMULTANEOUS TREATMENT OF OCULAR ROSACEA AND ACNE ROSACEA
US10105441B2 (en) * 2007-08-16 2018-10-23 The Schepens Eye Research Institute, Inc. Method for inhibiting or reducing dry eye disease by IL-1Ra
EP2335735A1 (en) 2009-12-14 2011-06-22 Novaliq GmbH Pharmaceutical composition for treatment of dry eye syndrome
CN113679697A (zh) 2012-09-12 2021-11-23 诺瓦利克有限责任公司 包含半氟化烷烃的混合物的组合物
DK3181119T3 (da) * 2012-09-12 2019-09-16 Novaliq Gmbh Semifluorerede alkansammensætninger til anvendelse ved behandling af keratoconjunctivitis sicca
CN106999402B (zh) * 2014-10-09 2020-10-27 梅迪普罗都司股份有限公司 睫毛用清洗剂
CN108348777B (zh) * 2015-09-30 2020-04-28 诺瓦利克有限责任公司 半氟化化合物和其组合物
ES2969758T3 (es) * 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
CN111182893A (zh) * 2017-10-04 2020-05-19 诺瓦利克有限责任公司 包含f6h8的眼用组合物

Also Published As

Publication number Publication date
US20250295607A1 (en) 2025-09-25
PH12021550621A1 (en) 2022-02-14
AU2025204313A1 (en) 2025-06-26
AU2019342426A1 (en) 2021-05-20
CA3111873A1 (en) 2020-03-26
EP3852734A1 (en) 2021-07-28
SG11202102818YA (en) 2021-04-29
CN112739335A (zh) 2021-04-30
US20210346313A1 (en) 2021-11-11
IL281516A (en) 2021-04-29
JP2022500461A (ja) 2022-01-04
WO2020058504A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
US20250295607A1 (en) Ophthalmic compositions for treatment of ocular surface damage and symptoms of dryness
US12569452B2 (en) Ophthalmic compositions comprising F6H8
US12059449B2 (en) Ophthalmic composition for treatment of dry eye disease
US8496976B2 (en) Artificial tears and therapeutic uses
Park et al. Clinical effects and safety of 3% diquafosol ophthalmic solution for patients with dry eye after cataract surgery: a randomized controlled trial
CN110267645A (zh) 用于治疗干眼病的眼用组合物
JP7571037B2 (ja) 眼表面疼痛を治療する方法
RU2806212C2 (ru) Офтальмологические композиции для лечения повреждения поверхности глаза и симптомов сухости глаз
CA3076567C (en) Ophthalmic compositions comprising f6h8
RU2828769C2 (ru) Офтальмологические композиции для лечения синдрома сухого глаза
HK40028751A (en) Ophthalmic compositions comprising f6h8
HK40114301A (en) Ophthalmic composition for treatment of dry eye disease
HK40058504A (en) Ophthalmic composition for treatment of dry eye disease
HK40058504B (en) Ophthalmic composition for treatment of dry eye disease
WO2025062471A1 (en) Compositions for treatment of dry eye syndrome or corneal wound healing
US20190224136A1 (en) Artificial tear compositions and methods of use thereof
Zhang Influence of local application of glaucoma medications-travoprost eye drops on patients' tear film function.
Lane the Eyedrop

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

E14-X000 Pre-grant third party observation filed

St.27 status event code: A-2-3-E10-E14-opp-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

E14 Pre-grant third party observation filed

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E14-OPP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E14-X000 Pre-grant third party observation filed

St.27 status event code: A-2-3-E10-E14-opp-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902